Kash Biotech Express

Antibodies discovery, IHC

kashbiotech
Amyloid Beta Elisa anti-Human beads Biotin blocking peptide Cell Based Elisa coli recombinant colorimetric Cy3 Cy7 gel gene Glutamate Assay Kit high Lipase Assay Kit Monomethyl Auristatin E Sa B Gal Sa Beta Gal Senescence Assay Senescence Beta Galactosidase Staining Kit Spoligotyping Transformation Assay Trap Assay Kit

Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic

Despite substantial progress in confronting the global HIV-1 epidemic since its inception in the 1980s, better approaches for both treatment and prevention will be necessary to end the epidemic and remain a top public health priority. Antiretroviral therapy (ART) has been effective in extending lives, but at a cost of lifelong adherence to treatment. Broadly neutralizing antibodies (bNAbs) are directed to conserved regions of the HIV-1 envelope glycoprotein trimer (Env) and can block infection if present at the time of viral exposure. The therapeutic application of bNAbs holds great promise, and progress is being made toward their development for widespread clinical use. Compared to the current standard of care of small molecule-based ART, bNAbs offer: (1) reduced toxicity; (2) the advantages of extended half-lives that would bypass daily dosing requirements; and (3) the potential to incorporate a wider immune response through Fc signaling. Recent advances in discovery technology can enable system-wide mining of the immunoglobulin repertoire and will continue to accelerate isolation of next generation potent bNAbs. Passive transfer studies in pre-clinical models and clinical trials have demonstrated the utility of bNAbs in blocking or limiting transmission and achieving viral suppression.

These studies have helped to define the window of opportunity for optimal intervention to achieve viral clearance, either using bNAbs alone or in combination with ART. None of these advances with bNAbs would be possible without technological advancements and expanding the cohorts of donor participation. Together these elements fueled the remarkable growth in bNAb development. Here, we review the development of bNAbs as therapies for HIV-1, exploring advances in discovery, insights from animal models and early clinical trials, and innovations to optimize their clinical potential through efforts to extend half-life, maximize the contribution of Fc effector functions, preclude escape through multiepitope targeting, and the potential for sustained delivery.

 

Symptoms, antibody levels and vaccination attitude after asymptomatic to moderate COVID-19 infection in 200 healthcare workers

 

Aim: In Germany, the willingness to be vaccinated against COVID-19 is rather low among medical staff. We collected data on symptoms, antibody titers and vaccination readiness from clinic employees at a municipal clinic who had already been through a COVID-19 infection (asymptomatic to moderate). We also examined the antibody titers for their possible importance as an individual decision-making aid with regard to vaccination.

 

Method: 200 employees of our municipal clinics were included in the study. COVID-19 antibody determination was performed using an ELISA (EUROIMMUN™, PerkinElmer, Inc. Company). The participants were given an anonymous questionnaire containing anthropometrical issues, symptoms of the infection and questions concerning the vaccination decision. Finally, the antibody levels were reported to the participants and the attitude towards a vaccination was reevaluated.

 

Results: In all 200 participants who had already gone through a COVID-19 infection, 75 employees were in favor of a vaccination (37.5%), 96 were opposed to vaccination (48%), and 29 were undecided (14.5%). In the different occupational groups, the positive trend in terms of willingness to be vaccinated was highest among physicians and is least among nurses. The antibody results showed considerable variation in titer levels and therefore did not correlate with disease severity in asymptomatic to moderately ill persons. We also observed a pro-vaccination trend with increasing age of the participants. The specifically-asked symptom of cutaneous hyperesthesia during COVID-19 infection occurred in 5% of the participants.

 

Conclusion: In medical personnel who had already suffered from a COVID-19 infection, the willingness to receive a vaccination tends to be highest among physicians, and lowest in nurses, and increases with age. For the vast majority of those affected, knowledge of the antibody titers only reinforces the vaccination decision made beforehand and thus does not contribute to a change in vaccination decision. The specifically-requested symptom of cutaneous hyperesthesia during COVID-19 infection was unexpectedly frequent.

kashbiotech
kashbiotech

Engineering a novel IgG-like bispecific antibody against enterovirus A71

Frequent outbreaks of enterovirus A71 (EVA71) occur in the Asia-Pacific area, and these are closely associated with severe neurological symptoms in young children. No effective antiviral therapy is currently available for the treatment of EVA71 infection. The development of monoclonal antibodies (mAbs) has demonstrated promise as a novel therapy for the prevention and treatment of infectious diseases. Several medical conditions have been treated using bispecific or multi-specific antibodies that recognize two or more distinct epitopes simultaneously. However, bispecific or multi-specific antibodies often encounter protein expression and product stability problems.

In this study, we developed an IgG-like bispecific antibody (E18-F1) comprising two anti-EVA71 antibodies: E18 mAb and llama-derived F1 single-domain antibody. E18-F1 was demonstrated to exhibit superior binding affinity and antiviral activity compared with E18 or F1. Additionally, E18-F1 not only improved survival rate, but also reduced clinical signs in human SCARB2 receptor (hSCARB2) transgenic mice challenged with a lethal dose of EVA71. Altogether, our results reveal that E18-F1 is a simple format bispecific antibody with promising antiviral activity for EVA71.

Myelin Oligodendrocyte Glycoprotein-antibody-associated Disorder Presenting with Corticomeningeal Encephalitis prior to the Onset of Optic Neuritis

We herein report a case of myelin oligodendrocyte glycoprotein-antibody-associated disorder (MOG-AD) presenting with corticomeningeal encephalitis. The patient exhibited oral ulceration, a mild impairment of consciousness, fever, nausea, nuchal rigidity, positivity for human leukocyte antigen type B51, and neutrophil-dominant pleocytosis and interleukin-6 level in cerebrospinal fluid (CSF). Magnetic resonance imaging (MRI) revealed a right temporal lesion with leptomeningeal gadolinium enhancement.

The initial diagnosis was neuro-Behçet’s disease presenting with meningoencephalitis; however, a cell-based assay detected anti-MOG antibody in the serum and CSF and the patient also experienced bilateral optic neuritis. After administering steroid therapy, his neurologic symptoms and CSF abnormalities improved along with the disappearance of gadolinium enhancement and the lesion on MRI. This case suggests that MOG-AD may present with corticomeningeal encephalitis prior to the onset of optic neuritis.

VEGF-A(VEGF/1063) Antibody
BNC801063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC811063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC811063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC701063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC701063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC881063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC881063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF488A conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC051063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC051063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC041063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC041063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405S conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC401063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC401063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF640R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCB1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCB1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Biotin conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCAP1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCAP1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCA1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCR1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCP1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNUM1063-50 50uL
EUR 474
Description: Primary antibody against VEGF-A(VEGF/1063), 1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCH1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNCH1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNUB1063-100 100uL
EUR 250.8
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody
BNUB1063-500 500uL
EUR 549.6
Description: Primary antibody against VEGF-A(VEGF/1063), Concentration: 0.2mg/mL

VEGF-A(VEGF/1063) Antibody
BNC611063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC611063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC551063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC551063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC431063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC431063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC681063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC681063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF568 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC471063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody
BNC471063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF647 conjugate, Concentration: 0.1mg/mL

Anti-VEGF/Vegfa Antibody
A00045 100ug/vial
EUR 352.8

Anti-VEGF/Vegfa Antibody
A00045-2 100ug/vial
EUR 352.8

Anti-VEGF/VEGFA Antibody
PB9071 100ug/vial
EUR 400.8

Anti-VEGF/VEGFA Antibody
PA1080 100ug/vial
EUR 400.8

VEGF antibody
10-2585 250 ug
EUR 590.4
Description: Mouse monoclonal VEGF antibody

VEGF antibody
10-2586 100 ug
EUR 289.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody
10R-7735 500 ug
EUR 678
Description: Mouse monoclonal VEGF antibody

VEGF antibody
10R-V101ax 100 ug
EUR 571.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody
10R-V101b 200 ug
EUR 805.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody
10R-V109A 500 ug
EUR 327.6
Description: Mouse monoclonal VEGF antibody

VEGF antibody
70R-VG001 100 ug
EUR 392.4
Description: Affinity purified Goat polyclonal VEGF antibody

VEGF antibody
70R-VR001x 50 ug
EUR 392.4
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody
70R-VR003 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody
70R-VR004 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody
70R-VR006 50 ug
EUR 327.6
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody
70-VR20 50 ug
EUR 392.4
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody
70R-11863 100 ul
EUR 536.4
Description: Goat polyclonal VEGF antibody

VEGF antibody
70R-11864 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF Antibody
5363-100 each
EUR 398.4

VEGF Antibody
5363-30T each
EUR 175.2

VEGF Antibody
5365-100 each
EUR 379.2

VEGF Antibody
5365-30T each
EUR 175.2

VEGF antibody
70R-12327 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody
70R-12328 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody
70R-12329 100 ug
EUR 483.6
Description: Rabbit polyclonal VEGF antibody

VEGF antibody
70R-13764 100 ug
EUR 418.8
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF Antibody
48707-100ul 100ul
EUR 399.6

VEGF Antibody
48707-50ul 50ul
EUR 286.8

VEGF Antibody
ABF5131 100 ug
EUR 525.6

VEGF antibody
PAab09933 100 ug
EUR 463.2

VEGF Antibody
R31500 100 ug
EUR 356.15
Description: VEGF is the only mitogen that specifically acts on endothelial cells. It may be a major regulator of tumor angiogenesis in vivo. It is structurally related to platelet-derived growth factor. VEGF shares homology with the PDGF A chain and B chain, including conservation of all 8 cysteines found in PDGFA and PDGFB. VEGF gene contains 8 exons. VEGF induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. And this gene also can regulate haematopoietic stem cell survival by an internal autocrine loop mechanism. What’s more, it also stimulates neurogenesis in vitro and in vivo.

VEGF Antibody
V8154-100UG 100 ug
EUR 349.3
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis.

VEGF Antibody
V8154-20UG 20 ug
EUR 153.3
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis.

VEGF Antibody
V8154SAF-100UG 100 ug
EUR 349.3
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis.

VEGF/ Rat VEGF ELISA Kit
ELA-E0143r 96 Tests
EUR 1063.2

VEGF
MO15067 500 ug
EUR 1092

VEGF
LF-PR009 10 ug
EUR 306
Description: VEGF protein

VEGF
PR15028 10 ug
EUR 553.2

VEGF 121
PR15029 5 ug
EUR 498

VEGF 162
PR15030 25 ug
EUR 553.2

VEGF 165
PR15031 50 ug
EUR 1477.2

VEGF 120
PR15033 5 ug
EUR 459.6

VEGF 164
PR15034 25 ug
EUR 1352.4

VEGF 164
PR15035 50 ug
EUR 1477.2

Human VEGF 121 Antibody
32562-05111 150 ug
EUR 313.2

Human VEGF 165 Antibody
32563-05111 150 ug
EUR 313.2

EG VEGF antibody
20R-1607 100 ug
EUR 807.6
Description: Rabbit polyclonal EG VEGF antibody

VEGF C antibody
20R-1831 100 ug
EUR 807.6
Description: Goat polyclonal VEGF C antibody

EG VEGF antibody
70R-EG002 50 ug
EUR 327.6
Description: Affinity purified Goat polyclonal EG VEGF antibody

VEGF-C Antibody
5633-100 each
EUR 444

VEGF-C Antibody
5633R-100 each
EUR 379.2

VEGF-C Antibody
5633R-30T each
EUR 175.2

VEGF-C Antibody
5634-100 each
EUR 379.2

VEGF-C Antibody
5634-30T each
EUR 175.2

VEGF-B Antibody
5641-100 each
EUR 379.2

VEGF-B Antibody
5641-30T each
EUR 175.2

VEGF-D Antibody
5643-100 each
EUR 379.2

VEGF-D Antibody
5643-30T each
EUR 175.2

VEGF-A Antibody
F41972-0.08ML 0.08 ml
EUR 140.25
Description: This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms.

VEGF-A Antibody
F41972-0.4ML 0.4 ml
EUR 322.15
Description: This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms.

VEGF-C Antibody
F47901-0.4ML 0.4 ml
EUR 322.15
Description: VEGFC is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor D.

VEGF-A/ Rat VEGF- A ELISA Kit
ELA-E1851r 96 Tests
EUR 1063.2

VEGF-B/ Rat VEGF- B ELISA Kit
ELA-E0144r 96 Tests
EUR 1063.2

VEGF-C/ Rat VEGF- C ELISA Kit
ELA-E0145r 96 Tests
EUR 1063.2

VEGF-D/ Rat VEGF- D ELISA Kit
ELA-E0146r 96 Tests
EUR 1063.2

human VEGF Antibody
E13-a001 100μg
EUR 458.4

Polyclonal VEGFA / VEGF Antibody
APR10713G 0.05mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VEGFA / VEGF . This antibody is tested and proven to work in the following applications:

VEGF antibody (biotin)
60R-V101cBT 50 ug
EUR 392.4
Description: Rabbit polyclonal VEGF antibody (biotin) conjugated

VEGF antibody (biotin)
60R-VG001bt 50 ug
EUR 457.2
Description: Goat polyclonal VEGF antibody (biotin) conjugated

VEGF antibody (biotin)
60R-VR001bt 50 ug
EUR 327.6
Description: Rabbit polyclonal VEGF antibody (biotin) conjugated

VEGF antibody (biotin)
60R-1093 25 ug
EUR 327.6
Description: Rabbit monoclonal VEGF antibody (biotin)

Rabbit Anti-Common N. American (Diamondback, copperhead and Mocacassin snakes) venom antiserum
CATX15-S 100 ul
EUR 548.4

Chicken Anti-Common N. American (Diamondback, copperhead and Mocacassin snakes) venom antiserum
CATX16-S 100 ul
EUR 548.4

Sheep Anti-Common N. American (Diamondback, copperhead and Mocacassin snakes) venom antiserum
CATX17-S 100 ul
EUR 548.4

VEGF, CF
PR15028CF 10 ug
EUR 553.2

VEGF Receptor Antibody
R31072 100 ug
EUR 356.15
Description: Vascular endothelial growth factor receptor 1(FLT1) is a protein that in humans is encoded by the FLT1 gene. Oncogene FLT belongs to the src gene family. Like other members of this family, it shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation.

VEGF-C
PR27170 2 ug
EUR 229.2

VEGF-B
RA26004 100 ul
EUR 646.8

VEGF-D
RA26005 100 ul
EUR 646.8

Goat(VEGF)
QY-E140039 96T
EUR 495.6

VEGF 121, CF
PR15029CF 5 ug
EUR 498

VEGF 162, CF
PR15030CF 25 ug
EUR 553.2

VEGF 165, CF
PR15031CF 50 ug
EUR 1477.2

VEGF 164, CF
PR15034CF 5 ug
EUR 459.6

VEGF 164, CF
PR15035CF 50 ug
EUR 1477.2

rHu VEGF-165
AK8295-0002 2µg Ask for price

rHu VEGF-165
AK8295-0010 10µg Ask for price

rHu VEGF-165
AK8295-0100 100µg Ask for price

rHu VEGF-165
AK8295-1000 1mg Ask for price

rHu VEGF-121
AK8331-0002 2µg Ask for price

rHu VEGF-121
AK8331-0010 10µg Ask for price

rHu VEGF-121
AK8331-0100 100µg Ask for price

rHu VEGF-121
AK8331-1000 1mg Ask for price

Polyclonal VEGF Antibody
APR10709G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VEGF . This antibody is tested and proven to work in the following applications:

Polyclonal VEGF Antibody
APR10710G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VEGF . This antibody is tested and proven to work in the following applications:

VEGF Monoclonal Antibody
30217-100ul 100ul
EUR 302.4

VEGF Monoclonal Antibody
30217-50ul 50ul
EUR 224.4

VEGF Conjugated Antibody
C48707 100ul
EUR 476.4

VEGF Polyclonal Antibody
A72296
  • EUR 302.50
  • EUR 423.50
  • 50 ul
  • 100 ul

VEGF Polyclonal Antibody
EA320-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against VEGF from Human/ Rat/ Mouse. This antibody is tested and validated for IHC

VEGF Polyclonal Antibody
EA320-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against VEGF from Human/ Rat/ Mouse. This antibody is tested and validated for IHC

VEGF-121-Fc
E13-m005-1 10μg
EUR 411.6

VEGF-121-Fc
E13-m005-2 50μg
EUR 1386

VEGF-165-Fc
E13-m006-1 10μg
EUR 411.6

VEGF-165-Fc
E13-m006-2 50μg
EUR 1386

Genorise® Anti-canine VEGF Polyclonal Antibody
GR105177 100 ug
EUR 438

Genorise® Anti-Equine VEGF Polyclonal Antibody
GR105195 100 ug
EUR 438

VEGF protein
30R-AV008 2 ug
EUR 152.4
Description: Purified recombinant Murine VEGF protein

Insulin-US Standard F
F282F 1 ml
EUR 234
Description: Insulin-US Standard F by Cygnus Technologies is available in Europe via Gentaur.

VEGF Receptor 1 / VEGFR1 Antibody
RQ4032 100 ug
EUR 356.15
Description: Vascular endothelial growth factor receptor 1 (FLT1) is a protein that in humans is encoded by the FLT1 gene. Oncogene FLT belongs to the src gene family. It is mapped to 13q12. The deduced 1,338-amino acid protein has a calculated molecular mass of 150.6 kD. It has a 758-amino acid extracellular domain, followed by a 22-amino acid transmembrane region and a 558-amino acid cytoplasmic region containing a cluster of basic amino acids and a tyrosine kinase domain. sFLT-1 was identified in placenta, adult lung, kidney, liver and uterus. Like other members of this family, it shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation.

VEGF Receptor 1 / VEGFR1 Antibody
RQ4033 100 ug
EUR 356.15
Description: Vascular endothelial growth factor receptor 1 (FLT1) is a protein that in humans is encoded by the FLT1 gene. Oncogene FLT belongs to the src gene family. It is mapped to 13q12. The deduced 1,338-amino acid protein has a calculated molecular mass of 150.6 kD. It has a 758-amino acid extracellular domain, followed by a 22-amino acid transmembrane region and a 558-amino acid cytoplasmic region containing a cluster of basic amino acids and a tyrosine kinase domain. sFLT-1 was identified in placenta, adult lung, kidney, liver and uterus. Like other members of this family, it shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation.

VEGF Receptor 3 Antibody / VEGFR3
RQ4081 100 ug
EUR 356.15
Description: Fms-related tyrosine kinase 4, also known as FLT4 or VEGFR3, is a protein which in humans is encoded by the FLT4 gene. It is mapped to 5q35.3. This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. FLT4 has an essential role in the development of the embryonic cardiovascular system before the emergence of the lymphatic vessels. It has been found that FLT4, which provides proangiogenic signaling when expressed on endothelium, may also have antiangiogenic properties when expressed at an avascular site by nonendothelial cells. FLT4 is also regarded as a regulator of vascular network formation.

VEGF Receptor 3 Antibody / VEGFR3
R32892 100 ug
EUR 356.15
Description: Fms-related tyrosine kinase 4, also known as FLT4 or VEGFR3, is a protein which in humans is encoded by the FLT4 gene. It is mapped to 5q35.3. This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. FLT4 has an essential role in the development of the embryonic cardiovascular system before the emergence of the lymphatic vessels. It has been found that FLT4, which provides proangiogenic signaling when expressed on endothelium, may also have antiangiogenic properties when expressed at an avascular site by nonendothelial cells. FLT4 is also regarded as a regulator of vascular network formation.

VEGF Recepr 2 Antibody
48346-100ul 100ul
EUR 399.6

VEGF Recepr 2 Antibody
48346-50ul 50ul
EUR 286.8

Antibody for Human VEGF
SPC-1291D 0.1ml
EUR 376.8
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is unconjugated.

Antibody for Human VEGF
SPC-1291D-A390 0.1ml
EUR 433.2
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 390.

Antibody for Human VEGF
SPC-1291D-A488 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 488.

Antibody for Human VEGF
SPC-1291D-A565 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 565.

Antibody for Human VEGF
SPC-1291D-A594 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 594.

Antibody for Human VEGF
SPC-1291D-A633 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 633.

Antibody for Human VEGF
SPC-1291D-A655 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 655.

Antibody for Human VEGF
SPC-1291D-A680 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 680.

Antibody for Human VEGF
SPC-1291D-A700 0.1ml
EUR 432
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 700.

Antibody for Human VEGF
SPC-1291D-ALP 0.1ml
EUR 426
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Alkaline Phosphatase.

Antibody for Human VEGF
SPC-1291D-APC 0.1ml
EUR 430.8
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to APC .

Antibody for Human VEGF
SPC-1291D-APCCY7 0.1ml
EUR 518.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to APC/Cy7.

Antibody for Human VEGF
SPC-1291D-BI 0.1ml
EUR 428.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Biotin.

Antibody for Human VEGF
SPC-1291D-DY350 0.1ml
EUR 523.2
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Dylight 350.

Antibody for Human VEGF
SPC-1291D-DY405 0.1ml
EUR 494.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Dylight 405.

Antibody for Human VEGF
SPC-1291D-DY488 0.1ml
EUR 471.6
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Dylight 488.

Antibody for Human VEGF
SPC-1291D-DY594 0.1ml
EUR 476.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Dylight 594.

Antibody for Human VEGF
SPC-1291D-DY633 0.1ml
EUR 464.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Dylight 633.

Antibody for Human VEGF
SPC-1291D-FITC 0.1ml
EUR 423.6
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to FITC.

Antibody for Human VEGF
SPC-1291D-HRP 0.1ml
EUR 418.8
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to HRP.

Antibody for Human VEGF
SPC-1291D-P594 0.1ml
EUR 440.4
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to PE/ATTO 594.

Antibody for Human VEGF
SPC-1291D-PCP 0.1ml
EUR 430.8
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to PerCP.

Antibody for Human VEGF
SPC-1291D-RPE 0.1ml
EUR 429.6
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to RPE .

Antibody for Human VEGF
SPC-1291D-STR 0.1ml
EUR 430.8
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Streptavidin.

VEGF Receptor 1 Antibody
48718-100ul 100ul
EUR 399.6

VEGF Receptor 1 Antibody
48718-50ul 50ul
EUR 286.8

VEGF Receptor 2 Antibody
48823-100ul 100ul
EUR 399.6

VEGF Receptor 2 Antibody
48823-50ul 50ul
EUR 286.8

Mouse Anti Human Vegf Receptor 1 Monoclonal Antibody
CABT-47861MH 0.1 mg
EUR 1070.4

Insula Lysate
XBL-10139 0.1 mg
EUR 663.9
Description: Human Insula tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human Insula tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the Insula tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The Insula tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Polyclonal VEGF-C Antibody
APG00009G 0.1mg
EUR 633.6
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human VEGF-C . This antibody is tested and proven to work in the following applications:

Polyclonal VEGF-B Antibody
APR00306G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VEGF-B . This antibody is tested and proven to work in the following applications:

Polyclonal VEGF-D Antibody
APR00307G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VEGF-D . This antibody is tested and proven to work in the following applications:
Tags:
Alternative non-antibody scaffolds for molecular recognition.
kashbiotech